Soleno Therapeutics (SLNO) Cash from Investing Activities (2013 - 2026)

Soleno Therapeutics (SLNO) has 13 years of Cash from Investing Activities data on file, last reported at $38.0 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 65.6% year-over-year to $38.0 million in Q1 2026; TTM through Mar 2026 was -$186.7 million, a 113.41% decrease from a year earlier, with the FY2025 full-year figure at -$201.8 million, up 10.59% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $38.0 million, up from -$125.4 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for SLNO reached as high as $38.0 million in Q1 2026 and fell as low as -$125.4 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$38.9 million across 4 years, with a median of -$4.0 million in 2022.
• On a YoY basis, Cash from Investing Activities climbed as much as 119.9% in 2025 and fell as far as 2363.44% in 2025.
• Year by year, Cash from Investing Activities stood at -$6000.0 in 2022, then jumped by 107483.33% to $6.4 million in 2024, then tumbled by 2045.68% to -$125.4 million in 2025, then soared by 130.3% to $38.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $38.0 million in Q1 2026, -$125.4 million in Q4 2025, and -$91.4 million in Q3 2025.